Systemic sagopilone (ZK-EPO) treatment of patients with recurrent malignant gliomas

Bevacizumab and Irinotecan in the Treatment of Recurrent Malignant Gliomas

(2010) John F. de Groot et al.   CANCER JOURNAL

Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience

(2008) Silvia Scoccianti et al.   ANTI-CANCER DRUGS

Improved Cellular Pharmacokinetics and Pharmacodynamics Underlie the Wide Anticancer Activity of Sagopilone

(2008) J. Hoffmann et al.   CANCER RESEARCH

New Therapeutic Options for Chemotherapy-Resistant Metastatic Breast Cancer

(2008) Paolo Pronzato   DRUGS

Sagopilone (ZK-EPO): from a natural product to a fully synthetic clinical development candidate

(2008) Ulrich Klar et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Sagopilone crosses the blood–brain barrier in vivo to inhibit brain tumor growth and metastases

(2008) Jens Hoffmann et al.   NEURO-ONCOLOGY